Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue
A Prospective, Multi-center, Randomized Controlled, Non-inferiority Study to Evaluate the Safety and Effectiveness of ULTRAFORMER MPT PLUS Treatment to Lift Lax Submental (Beneath the Chin) and Neck Tissue
CLASSYS Inc.
273 participants
Oct 16, 2025
INTERVENTIONAL
Conditions
Summary
This is a prospective, multicenter, randomized, evaluator-blinded, parallel-controlled, non-inferiority clinical study designed to evaluate the safety and effectiveness of the ULTRAFORMER MPT PLUS, a high-intensity focused ultrasound (HIFU) device, for lifting and tightening lax submental (beneath the chin) and neck tissue in adult subjects. Approximately 273 subjects will be enrolled at multiple investigational sites across the United States. Participants will receive either the ULTRAFORMER MPT PLUS treatment or the predicate comparator device, and will be followed for safety and efficacy assessments including clinical photography, investigator evaluation, and patient-reported outcomes. The study aims to demonstrate that ULTRAFORMER MPT PLUS is non-inferior to the approved reference device in improving skin laxity and wrinkle appearance of the lower face and neck.
Eligibility
Inclusion Criteria6
- Male or female subjects aged 30 to 65 years, inclusive, at the time of informed consent.
- Subjects presenting with mild to moderate submental and/or neck skin laxity, as determined by the investigator.
- Subjects in good general health with stable body weight (±5%) for at least 6 months prior to screening.
- Subjects willing to avoid other aesthetic or dermatologic procedures (surgical or non-surgical) to the treatment area during the study period.
- Subjects able to understand and sign informed consent and comply with all study visits and procedures.
- Female subjects of child-bearing potential who agree to use reliable contraception throughout study participation.
Exclusion Criteria10
- Prior facelift, neck lift, liposuction, or contouring surgery involving the lower face, submental, or neck areas.
- Receipt of any energy-based aesthetic treatment (e.g., HIFU, radiofrequency, laser) or injectable aesthetic treatment (e.g., botulinum toxin, dermal filler, collagen stimulator) to the treatment area within 6 months prior to baseline.
- Presence of any implanted electronic medical device, such as a pacemaker, defibrillator, or neurostimulator.
- Active skin infection, wound, cystic acne, inflammation, or severe scarring within or near the treatment area.
- History of keloid formation or abnormal wound healing.
- Known bleeding disorder, or use of anticoagulant or antiplatelet medications that cannot be safely discontinued for the procedure.
- Pregnant or breastfeeding women.
- Subjects with a known sensitivity or contraindication to ultrasound-based procedures.
- Any medical or psychiatric condition that, in the investigator's judgment, could interfere with study participation, safety, or data integrity.
- Participation in another investigational study within 30 days prior to screening.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
ULTRAFORMER MPT PLUS (Classys Inc., Seoul, Korea) is a high-intensity focused ultrasound (HIFU) system that delivers focused energy at multiple depths to induce neocollagenesis and tissue contraction for non-surgical lifting and tightening of submental and neck tissue. The device includes both Default and MP modes and is under investigation under FDA IDE G250041.
The Ulthera System (Merz Aesthetics, USA) is an FDA-cleared high-intensity focused ultrasound (HIFU) device indicated for non-invasive lifting and tightening of lax tissue in the submental and neck areas. It serves as the active comparator for this non-inferiority clinical study.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07229430